Related Experiment Video
Updated: Jan 8, 2026

The Goeckerman Regimen for the Treatment of Moderate to Severe Psoriasis
Published on: July 11, 2013
Generalized Linear Porokeratosis Treated With Ixekizumab
Yihe Zheng1, Yunhao Zhu2, Jianjun Qiao1
1Department of Dermatology, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China.
Abstract:
We reported a 15-year-old boy with extensive linear porokeratosis confirmed by clinical, histopathologic, and immunohistochemical assessment. Ixekizumab treatment lead to a near-complete clearance of lesions by 3 months, while nail dystrophy showed minimal response. The presence of IL-17A-positive infiltrates supported the immunologic basis for therapeutic efficacy. These findings suggest that ixekizumab is a promising targeted therapy for refractory linear porokeratosis.
Insights
Ixekizumab effectively treated extensive linear porokeratosis (LP) in a young patient, achieving near-complete lesion clearance. While skin lesions responded well, nail dystrophy showed limited improvement, suggesting targeted therapy potential for refractory LP.
Area of Science:
- Dermatology
- Immunology
- Clinical Therapeutics
Background:
- Linear porokeratosis (LP) is a rare, chronic skin disorder.
- Treatment options for extensive or refractory LP are limited.
- The role of interleukin-17A (IL-17A) in LP pathogenesis is under investigation.
More Related Videos
Related Concept Videos
Skin Cancer
Basal Cell Carcinoma (BCC): BCC is the most common type of skin cancer, accounting for about 80% of cases. It typically develops in...
Clinical Applications of Epidermal Stem Cells

